1. Allred DC, Swanson PE (2000) Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 113: 171–175
2. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P et al (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087–4091
3. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV (2001) Epidermal growth factor receptor and HER-2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clinical Cancer Res 7: 1850–1855
4. Bunn PA, Helfrich B, Soriano A, Franklin WA, Varella-Garcia M, Hirsch F, Baron A, Zeng C, Chan D (2001) Expression of HER-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and relationship to in vitro cytotoxicity by trastuzumab and cytotherapeutic. Clinical Cancer Research 7: 3239–3250
5. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648